Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 8, 2001, Pages 725-733

  Stanger, O ^a   Weger, M ^a   Renner, W ^a   Konetschny, R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Coagulation; Endothelium; Free radicals; Homocysteine

Indexed keywords

HOMOCYSTEINE; METHIONINE; VITAMIN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CONTROLLED STUDY; ENDOTHELIUM INJURY; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOSIS; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION;

ENDOTHELIUM, VASCULAR; FREE RADICALS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHIONINE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; OXIDATIVE STRESS; VASCULAR DISEASES; VENOUS THROMBOSIS;

EID: 0034821059     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.121     Document Type: Article

References (88)

1. Plasma homocysteine and venous thromboembolism
2. Homocysteine and cardiovascular disease
3. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland
4. Pathological findings in homocystinuria
5. Homocystinuria: An enzymatic defect
6. 12 metabolism leading to homocystinuria; cystathioninemia and methylmalonic aciduria
7. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
8. The pathogenesis of coronary artery disease: A possible role for methionine metabolism
9. Hyperhomocyst(e)inemia: A common and easily reversible risk factor for occlusive disease
10. Hyperhomocysteinemia: An independent risk factor for vascular disease
11. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease
12. Total homocysteine and cardiovascular risk factor. The Hordaland homocysteine study
13. Plasma homocysteine levels and mortality in patients with coronary artery disease
14. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease
15. Methionine metabolism in mammals
16. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy
17. S-Adenosylmethionine and methylation
18. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of nontransformed, transformed, proliferating, and quiescent cells in culture
19. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine
20. The growth-promoting properties of homocystine when added to a cystine-deficient diet and the proof of the structure of homocystine
21. Kinetics of plasma homocysteine in healthy subjects after peroral homocysteine loading
22. Radioenzymic determination of homocysteine in plasma and urine
23. Homocysteine species as components of plasma redox thiol status
24. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria
25. Improved vascular endothelial function after oral B vitamins. An effect mediated through reduced concentrations of free plasma homocysteine
26. Synthesis of homocysteine thiolactone by methionyl-tRNA synthethase in cultured mammalian cells
27. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro
28. Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans
29. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
30. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme
31. Activated protein C decreases plasminogen-activator-inhibitor activity in endothelial cell-conditioned medium
32. Generation of fibrinolytic activity by infusion of activated protein C in dogs
33. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase
34. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor
35. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine
36. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine
37. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells
38. Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator
39. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells
40. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
41. Role of von Willebrand factor in platelet adhesion to the subendothelium
42. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmatic reticulum
43. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan
44. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells
45. The role of tissue factor in the production of thrombin
46. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells
47. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
48. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
49. Vascular endothelial cells synthesize nitric oxide from L-arginine
50. 2 formation
51. Endothelins
52. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins
53. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
54. Stimulation of endothelial nitric oxide production by homocyst(e)ine
55. Endothelial dysfunction in cardiovascular disease. The role of oxidant stress
56. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury
57. Generation of superoxide free radicals during the autooxidation of thiols
58. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
59. Hyperhomocysteinemia and atherothrombosis
60. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
61. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and-independent mechanisms
62. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits
63. Lipid peroxidation induced in vivo by hyperhomocysteinemia in pigs
64. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels
65. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation
66. The pathogenesis of atherosclerosis - A perspective for the 1990's
67. Endothelial marker proteins in hyperhomocysteinemia
68. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease
69. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
70. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
71. Forearm composition contributes to differences in reactive hyperaemia between healthy men and women
72. Close relation of endothelial function in the human coronary and peripheral circulations
73. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease
74. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
75. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
76. Acute hyperhomocysteinaemia and endothelial dysfunction
77. Endothelial dysfunction during acute methionine load in hyperhomocysteinemic patients
78. Familial hyperhomocysteinemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries
79. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
80. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocyteinamia. An effect reversible with vitamin C therapy
81. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults
82. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects
83. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials
84. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia
85. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
86. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
87. Influence of folic acid on postprandial endothelial dysfunction
88. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease